15 Jan Avista Therapeutics
Robert Lin, Ph.D., CEO
April 28 | 1:45pm | Salone dei Cavalieri, Section 1
Pittsburgh, PA
(Private)
Avista utilizes an AI-guided platform to engineer AAVs for tissue-specific delivery of genetic medicines. ATX002 is a best-in-class intravitreal capsid that outperforms the previous industry standard (AAV2.7m8) by up to 30x. This increased performance can benefit patients through reduced dosing resulting in reduce inflammatory responses. Our partner Roche is utilizing this capsid for larger ophthalmic indications, while Avista is pursuing rare inherited retinal disease treatments using ATX002. With our numerous high-quality datasets from non-human primate experiments, Avista has created a machine learning platform to further drive our engineered AAV platform. We are currently testing further advances in the intravitreal capsid field. Additionally, we are leveraging the AI-platform to revolutionalize AAV local delivery to the brain. By creating targeted capsids, Avista will enable delivery of genetic medicines with AAVs that can be delivered at much lower dose levels to reduce immunotoxicity and provide safer treatments for patients.
